Clinical Trials Logo

Chemotherapy-Induced Neutropenia clinical trials

View clinical trials related to Chemotherapy-Induced Neutropenia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04887831 Terminated - Bladder Cancer Clinical Trials

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

PRESERVE3
Start date: June 4, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer.

NCT ID: NCT03559387 Terminated - Clinical trials for Chemotherapy-induced Neutropenia

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Start date: August 3, 2017
Phase: Phase 2
Study type: Interventional

Randomized, Open-Label study to determine the dose, efficacy, safety and pharmacokinetic profile of ANF-RHO™ with once-per-cycle injection in comparison with Neulasta in Breast Cancer patients at high risk of developing Chemotherapy-Induced Neutropenia

NCT ID: NCT02454530 Terminated - Clinical trials for Chemotherapy-Induced Neutropenia

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

VISTA
Start date: September 2014
Phase:
Study type: Observational

The aim of this study is to describe in real-life conditions the determinants of use of GCSF (Granulocyte Colony-Stimulating Factor) Nivestim® in primary or secondary prophylaxis and in patients receiving chemotherapy for solid tumour according to the chemotherapy context: adjuvant or metastatic setting.